CG Oncology price target raised to $72 from $65 at BofA

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)

CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential

CG Oncology Is Maintained at Buy by HC Wainwright & Co.

Earnings Flash (CGON) CG Oncology Posts 2025 Total Revenue $4M, vs. FactSet Est of $2.8M

CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate

CGON FY 2025 G&A expenses rise 118.1% to USD 73.5 million

CG Oncology Inc - Has $903 Mln Cash ,Cash Equivalents and Marketable Securities Sufficient to Fund Operations Into H1 2029

Press Release: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN)

CG Oncology's Creto Launch Could See Headwind From Reimbursement Incentives, RBC Says

CG Oncology Is Maintained at Buy by Truist Securities

CG Oncology Is Maintained at Outperform by RBC Capital

RBC Raises Price Target on CG Oncology to $73 From $61, Keeps Outperform, Speculative Risk

CG Oncology price target raised to $73 from $61 at RBC Capital

CG Oncology Is Maintained at Overweight by Piper Sandler

CG Oncology price target raised to $70 from $55 at Piper Sandler

CG Oncology Expands At-The-Market Equity Offering Capacity